Correction: Clinical review: Prothrombin complex concentrates - evaluation of safety and thrombogenicity by Sørensen, Benny et al.
Correction
After publication of our article [1] we noted that in Table 1 
for Prothrombinex-VF ‘Antithrombin and heparin added’ 
should have been included under the ‘Additional infor-
mation’ column. A copy of the table with the correct 
infor  mation can be found overleaf.
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© 2011 BioMed Central LtdTable 1. Composition of PCCs in the World Federation of Hemophilia register of clotting factor concentrates
  International units relative to factor IX
    Factor Factor  Factor Factor    Additional
Brand name  Manufacturer  II  VII  IX  X  Viral inactivation  information
Bebulin VH  Baxter BioScience,   120  (13)  100  100  Vapour heat, 60°C for 10 hours at 190 mbar,  Heparin added
  Austria           then 80°C for 1 hour at 375 mbar
Beriplex P/N  CSL Behring,   128  68  100  152  Pasteurisation at 60°C for 10 hours, and   Protein C; 
  Germany       nanofi   ltration  antithrombin,  heparin 
           and  albumin  added
Cofact  Sanquin,   56-140  28-80  100  56-140  Solvent/detergent and 15 nm  Antithrombin added
  the  Netherlands       nanofi   ltration
KASKADIL  LFB, France  148  40  100  160  Solvent/detergent  Heparin added
Octaplex  Octapharma, Austria   44-152  36-96  100  50  Solvent/detergent and nanofi  ltration  Heparin added; low
  and  France           activated  factor  VII 
           content
Profi  lnine SD  Grifols, USA  148  (11)  100  64  Solvent/detergent  –
Prothrombinex VF  CSL Bioplasma,   100  (–)  100  100  Dry heat, 80°C for 72 hours and  Antithrombin and
  Australia       nanofi   ltration  heparin  added
Prothromplex T  Baxter BioScience,   100  85  100  100  Vapour heat, 60°C for 10 hours at 190 mbar,  Antithrombin and
  Austria           then 80°C for 1 hour at 375 mbar  heparin added
UMAN Complex D.I.  Kedrion, Italy  100  (–)  100  80  Solvent/detergent and dry heat, 100°C for   Antithrombin and
         30  minutes  heparin  added
Composition of prothrombin complex concentrates (PCCs) listed in the World Federation of Hemophilia register of clotting factor concentrates [54], excluding 
concentrates for national markets only or for which the concentrations of factors relative to factor IX were not available from the relevant product information sheets. 
Factor VII presented in parentheses for three-factor PCCs.
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